DT Weekly Roadshow: Five critical changes the Medtech industry has experienced over past two years
This week’s discussion begins on the stage in Las Vegas where Tom Salemi interviewed Kwame Ulmer of Ulmer Ventures and Medtech Color at Medmarc’s annual broker meeting.
This episode is sponsored by Medmarc.
The conversation hit upon five areas that have changed over the past two years due to the pandemic or critical concerns over equity and fairness.
In this podcast, Ulmer speaks to the slow progress being made in medtech in diversifying the workforce. But he also offers signs of hope and introduced Medtech Color.
Ulmer will also speak to improvements made at the FDA, where he started his medtech career. He also provides an update on a comprehensive survey of the FDA being conducted by the biomed program at UCLA.
We’ll also hear post-conference interviews with Jennifer Fried, CEO of Explorer Surgical, who will share how that company successfully pivoted during the pandemic.
Mark Leahey, CEO of MDMA, will update on the MCIT ruling that would deliver surer reimbursement for medical device companies with breakthrough products.
Finally, Jonathan Norris of Silicon Valley Bank shares surprising changes to early and late-stage financings as well as medical device exits.
Subscribe to this podcast on all major podcast applications.
This episode is sponsored by Medmarc.
The conversation hit upon five areas that have changed over the past two years due to the pandemic or critical concerns over equity and fairness.
In this podcast, Ulmer speaks to the slow progress being made in medtech in diversifying the workforce. But he also offers signs of hope and introduced Medtech Color.
Ulmer will also speak to improvements made at the FDA, where he started his medtech career. He also provides an update on a comprehensive survey of the FDA being conducted by the biomed program at UCLA.
We’ll also hear post-conference interviews with Jennifer Fried, CEO of Explorer Surgical, who will share how that company successfully pivoted during the pandemic.
Mark Leahey, CEO of MDMA, will update on the MCIT ruling that would deliver surer reimbursement for medical device companies with breakthrough products.
Finally, Jonathan Norris of Silicon Valley Bank shares surprising changes to early and late-stage financings as well as medical device exits.
Subscribe to this podcast on all major podcast applications.
Activity